Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Epilepsy

Update to guidelines on treatment of infantile spasms

An evidence-based update to the 2004 guidelines for the treatment of infantile spasms has recently been published. Important new recommendations include use of low-dose adrenocorticotropic hormone (ACTH) over high-dose ACTH or vigabatrin. A paucity of data, however, leaves several key questions unanswered.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Riikonen, R. in Long-term Evolution of Epileptic Encephalopathies (eds Nikanorova, M. et al.) 13–28 (John Libbey Eurotext, Esher, 2009).

    Google Scholar 

  2. Go, C. et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 78, 1974–1980 (2012).

    Article  CAS  PubMed Central  Google Scholar 

  3. Mackay, M. T. et al. Practice parameter: medical treatment of infantile spasms: report of American Academy of Neurology and Child Neurology Society. Neurology 62, 1668–1681 (2004).

    Article  CAS  PubMed Central  Google Scholar 

  4. Lux, A. L. et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomized controlled trial. Lancet 364, 1773–1778 (2004).

    Article  CAS  PubMed Central  Google Scholar 

  5. Riikonen, R. Long-term outcome of patients with West syndrome. Brain Dev. 23, 683–687 (2001).

    Article  CAS  PubMed Central  Google Scholar 

  6. Darke, K. et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multicentre randomized trial. Arch. Dis. Child. 95, 382–386 (2010).

    Article  PubMed Central  Google Scholar 

  7. Riikonen, R., Jääskeläinen, J. & Turpeinen, U. Insulin-like growth factor-1 is associated with cognitive outcome in infantile spasms. Epilepsia 51, 1283–1289 (2010).

    Article  CAS  PubMed Central  Google Scholar 

  8. Bittigau, P. Sifringer, M. & Ikonomidou, C. Antiepileptic drugs and apoptosis in the developing brain. Ann. NY Acad. Sci. 993, 103–114 (2003).

    Article  CAS  PubMed Central  Google Scholar 

  9. Moskowitz, A., Hansen, R. M., Eklund, S. E. & Fulton, A. B. Electroretinographic (ERG) responses in pediatric patients using vigabatrin. Doc. Ophthalmol. 124, 197–209 (2012).

    Article  PubMed Central  Google Scholar 

  10. Riikonen, R. Does vigabatrin treatment for infantile spasms bring visual field defects? Presented at the Joint 12th International Child Neurology Congress and 11th Asian and Oceanian Congress of Child Neurology, http://icnapedia.org/lectures/53-icnc2012/sig-meetings/2484-vigabatrin-visual-field-defects (2012).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riikonen, R. Update to guidelines on treatment of infantile spasms. Nat Rev Neurol 8, 480–482 (2012). https://doi.org/10.1038/nrneurol.2012.157

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2012.157

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing